BAM
GMAB icon

Belpointe Asset Management’s Genmab GMAB Stock Holding History

Belpointe Asset Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,186
Closed -$82.5K – 1661
2023
Q1 		$82.5K Buy
2,186
+163
+8% +$6.26K ﹤0.01% 1422
2022
Q4 		$85.7K Buy
+2,023
New +$83.4K 0.01% 1325

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Belpointe Asset Management's GMAB Position: Q2 2023 in Review

Belpointe Asset Management sold out of Genmab (GMAB) in Q2 2023, closing a stake of 2,186 shares — an estimated $82.5K sold.

Belpointe Asset Management first reported a position in GMAB in Q4 2022 and held it in 2 quarters. The position peaked at $85.7K in Q4 2022. 213 funds tracked by Wall St. Rank hold GMAB as of Q2 2023.

  • Belpointe Asset Management reported no remaining Genmab position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 2,186 Genmab shares in Q2 2023, an estimated $82.5K.
  • Belpointe Asset Management first reported a position in Genmab in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Genmab position peaked at $85.7K in Q4 2022.
  • 213 funds tracked by Wall St. Rank held Genmab as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.